is the fda taking tirzepatide off the market Eli Lilly's FDA's drug shortage list: Here's what it means FDA Approves Tirzepatide, A Potential

Theyll check your levels, dosage, and medical history to greenlight you for donating safely

Step 1: Apply Pressure If you see bleeding at the site, use a clean gauze pad or cotton ball to apply firm, steady pressure for at least two minutes

Mar 1 2022;12(1):3401

Bypassing Gastrointestinal Factors By using sublingual administration, Keystone Pharmacys Semaglutide formulation avoids the gastrointestinal tract, which can often hinder drug absorption due to the acidic environment and digestive enzymes

ChAdOx/MVA viral vectors / CancerProstate cancerPhase 1Pursuing partnership opportunities for advancementWorldwide rights 3assets LOQTORZI (toripalimab-tpzi)LOQTORZI / PD-1 / Anti-PD-1 monoclonal antibody / Oncology1L Nasopharyngeal Carcinoma (combo with chemotherapy)ApprovedApprovedUnited States2L+ Nasopharyngeal Carcinoma (monotherapy)ApprovedApprovedUnited States TagmokitugCHS-114 / CCR8 / Anti-CCR8 monoclonal antibody / Oncology4L+ Colorectal Cancer (combo with toripalimab)Phase 22L HNSCC (combo with toripalimab)Phase 12L Gastric Cancer/GEJ/EAC (combo with toripalimab)Phase 1 CasdozokitugIL-27 / IL-27 antagonist monoclonal antibody / Oncology1L Hepatocellular Carcinoma (combo with toripalimab + bevacizumab)Phase 2 3assets CTx-1301CTx-1301 / PTR multi-core modified-release dexmethylphenidate tablet / CNSADHDNDA submittedSubmitted July 31, 2025US CTx-1302CTx-1302 / PTR multi-core modified-release dextroamphetamine tablet / CNSADHDPreclinical/formulationInitial formulation study plannedUS CTx-2103CTx-2103 / 5-HT1A partial agonist / PTR multi-core modified-release buspirone tablet / CNSAnxietyPre-INDClinical trials planned 4Q 2026US 3assets Iopofosine I 131CLR 131 / tumor cells via phospholipid drug conjugate delivery / PDC radiotherapeutic

Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity